Medicare Rx Plans Likely To Focus On Managing Use Of Low-Cost Drugs, AEI Rep Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Because catastrophic drug costs will be picked up by the government under Part D, private Medicare drug plans may have little incentive to manage use of high-cost biotech products, American Enterprise Institute Resident Fellow Gottlieb says. However, high government spending eventually could lead to political backlash.